We've run a phase two trial in Switzerland on, again, recurrent patients -- patients who have received standard therapy and whose cancer has come back.
U drugoj smo fazi ispitivanja u Švicarskoj, opet na pacijentima kojima se rak vratio -- pacijentima koji su dobili standardnu terapiju i čiji se rak vratio.